SCHEMBL7142468

SCHEMBL7142468

N#Cc1cc(C(=O)CC(=O)Nc2cc(-c3ccc(F)cc3F)ccc2NC(=O)O)ccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
KLKB1 P03952 3/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
USP2 O75604 1/20 0.34
DHFR P00374 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
LMNA P02545 1/20 0.34
TTR P02766 1/20 0.34
ALB P02768 1/20 0.34
HMGB1 P09429 1/20 0.34
CXCL12 P48061 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7469836 0.90 MAOB (0.41) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL5868993 0.87 CYP17A1 (0.40) ALOX5APFEN1TP53
SCHEMBL5868818 0.78 CYP17A1 (0.41) ALOX5APFEN1MAPT
SCHEMBL6609589 0.77 MAPT (0.38) MEN1KMT2AALDH1A1HPGDPOLB
SCHEMBL7464541 0.77 BCHE (0.36) MEN1KMT2AALDH1A1MYCMAPT
SCHEMBL5868769 0.77 CYP17A1 (0.45) HDAC2MYCMAOB
SCHEMBL7455415 0.76 RAF1 (0.36) ALDH1A1RAB9A
SCHEMBL7527939 0.76 RAB9A (0.38) MEN1KMT2AALDH1A1RAB9A
SCHEMBL7465211 0.76 GSK3B (0.40) CYP3A4CYP2C9KDM4EALDH1A1RAB9A
SCHEMBL7704536 0.72 DHODH (0.36) MEN1KMT2AALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6509328-B1 Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others HOFFMANN-LA ROCHE INC. 2003-01-21 US disclosed